Analysts have set 12-month price targets for DexCom, revealing an average target of $97.15, a high estimate of $106.00, and a ...

Fintel reports that on October 21, 2025, Stifel reiterated coverage of DexCom (NasdaqGS:DXCM) with a Buy recommendation.

Earlier this month, DexCom reported stronger-than-expected second quarter revenues but issued the weakest full-year outlook among patient monitoring peers, following a sector-wide selloff triggered by ...

In a report released on October 3, Joanne Wuensch from Citi reiterated a Buy rating on Dexcom, with a price target of $85.00. The company’s shares closed yesterday at $66.36. El ...

If you’re trying to figure out whether now’s the time to buy, hold, or even sell DexCom stock, you’re not alone. After all, its share price has been a bit of a roller coaster lately. Over the last ...

DexCom (DXCM) shares are in the spotlight after the company delivered better-than-expected second quarter revenues. However, a softer full-year outlook has drawn investor caution. Sector-wide trade ...

We came across a bearish thesis on DexCom, Inc. on Hunterbrook’s Substack. In this article, we will summarize the bulls’ ...

At the 61st annual European Association for the Study of Diabetes Conference (EASD) this week in Vienna, Austria, glucose monitoring company Dexcom introduced its new offering, the Dexcom Smart Basal, ...

DexCom's devices are important to its customers' health. The company still has significant whitespace in its market. Despite potential obstacles, the stock is still attractive. Even so, the ...